INBX
NasdaqINHIBRX BIOSCIENCES, INC.
Basic Materials · Biological Products, (No Diagnostic Substances)
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
🔒 price chart needs market-data feed$1.8M
2023
$200,000
2024
$1.3M
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$1.3M
Net Income$-140.1M
Gross Profit—
Oper Income$-135.0M
EPS (dil)$-9.04
Rev/sh$0.09
FCF/sh$-8.85
Book/sh$0.54
Gross M—
Oper M-10386.5%
Profit M-10773.5%
FCF M-9986.5%
ROE-1752.2%
ROA-95.6%
ROIC—
R&D/Rev8694.5%
Rev Y/Y550.0%
Rev 3Y CAGR—
EPS Y/Y-108.0%
EPS 3Y CAGR—
FCF 3Y CAGR—
Payout—
Div/sh—
Shs Chg Y/Y+3.4%
Current Ratio3.93
Quick Ratio—
Debt/Eq12.58
Int Coverage-11.1×
Net Debt$23.7M cash
Total Debt$100.6M
Cash & Eq$124.2M
Total Assets$146.5M
Oper CF$-129.8M
Capex$31,000
Free CF$-129.8M
Buybacks—
Equity$8.0M
Liabilities$138.5M
Shs Outstand0.01B
SectorBasic Materials
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 3 FY| USD | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | $1.8M | $200,000 | $1.3M |
| Gross Profit | — | — | — |
| Operating Income | $-219.2M | $-331.4M | $-135.0M |
| Net Income | $-241.4M | $1.7B | $-140.1M |
| Diluted EPS | $-20.48 | $112.62 | $-9.04 |
| Operating Cash Flow | $-193.3M | $-194.4M | $-129.8M |
| Free Cash Flow | $-197.9M | $-197.0M | $-129.8M |
COMMUNITY · $INBX0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.